Nitric Oxide Inhibits the Proliferation and Invasion of Pancreatic Cancer Cells through Degradation of Insulin Receptor Substrate-1 Protein

Nitric oxide (NO), which plays a role in the posttranslational modification of proteins, exhibits tumoricidal activity. However, the mechanism remains largely unclear. We investigated whether the regulation of insulin receptor substrate (IRS)-1 protein expression and insulin/insulin-like growth factor (IGF) signaling by NO is involved in the proliferation and invasion of pancreatic cancer cells. NO donor inhibited insulin/IGF-I–stimulated phosphorylation of insulin receptor/IGF-I receptor, IRS-1, Akt/PKB, and glycogen synthase kinase-3β along with decreased expression of IRS-1 protein in MIAPaCa-2 cells, whereas NO donor enhanced the phosphorylation of extracellular signal-regulated kinase-1/2. In contrast, a selective inducible nitric oxide synthase inhibitor, 1400W, upregulated the expression of IRS-1 protein and the phosphorylation of IRS-1, Akt/PKB, and glycogen synthase kinase-3β, along with enhanced proliferation and invasion of Panc-1 cells expressing inducible nitric oxide synthase protein. NO donor induced IRS-1 protein reduction through increased ubiquitination and degradation. For the detection of the site responsible for NO-induced ubiquitination, IRS-1 deletion mutant genes were transfected and overexpressed in MIAPaCa-2 cells. The results indicate that the COOH terminus of the IRS-1 protein is required for NO donor–induced ubiquitination and protein degradation. Cells stably transfected with COOH-terminal deletion mutants of IRS-1 exhibited reduced IGF signaling and cell proliferation compared with vector alone–transfected cells, with no influence of NO on IGF signaling and invasion, although stable transfectants with full-length IRS-1 protein exhibited remarkable NO-induced reduction in IGF signaling, cell proliferation, and invasion. These findings indicate that NO inhibits the proliferation and invasion of pancreatic cancer cells, at least in part, through upregulation of IRS-1 protein degradation and resultant downregulation of the insulin/IGF-I-Akt pathway. Mol Cancer Res; 8(8); 1152–63. ©2010 AACR.

[1]  D. Hirst,et al.  Nitric oxide synthase gene therapy enhances the toxicity of cisplatin in cancer cells , 2009, The journal of gene medicine.

[2]  J. Esplugues,et al.  Endothelial nitric oxide synthase regulates N-Ras activation on the Golgi complex of antigen-stimulated T cells , 2008, Proceedings of the National Academy of Sciences.

[3]  K. Lim,et al.  Tumour maintenance is mediated by eNOS , 2008, Nature.

[4]  Takuya Kato,et al.  An actin-binding protein Girdin regulates the motility of breast cancer cells. , 2008, Cancer research.

[5]  N. Seidah,et al.  Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. , 2008, The Journal of clinical investigation.

[6]  Xiaopeng Gao,et al.  l-Arginine Reduces Cell Proliferation and Ornithine Decarboxylase Activity in Patients with Colorectal Adenoma and Adenocarcinoma , 2007, Clinical Cancer Research.

[7]  Renato Baserga,et al.  Micro RNA 145 Targets the Insulin Receptor Substrate-1 and Inhibits the Growth of Colon Cancer Cells* , 2007, Journal of Biological Chemistry.

[8]  Carol L. Williams,et al.  Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. , 2007, Cancer research.

[9]  A. Sacchetti,et al.  EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  J. Kutok,et al.  JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. , 2007, Blood.

[11]  P. Krammer,et al.  Up‐regulation of Fas (CD95) expression in tumour cells in vivo , 2007, Immunology.

[12]  Adrian V. Lee,et al.  Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and Snail , 2007, Molecular and Cellular Biology.

[13]  M. Kampa,et al.  Resveratrol exerts its antiproliferative effect on HepG2 hepatocellular carcinoma cells, by inducing cell cycle arrest, and NOS activation. , 2006, Biochimica et biophysica acta.

[14]  Adrian V. Lee,et al.  Mammary Tumorigenesis and Metastasis Caused by Overexpression of Insulin Receptor Substrate 1 (IRS-1) or IRS-2 , 2006, Molecular and Cellular Biology.

[15]  L. Feig,et al.  The R-Ras GTPase Mediates Cross Talk between Estrogen and Insulin Signaling in Breast Cancer Cells , 2006, Molecular and Cellular Biology.

[16]  H. Friess,et al.  The Neurotrophic Factor Artemin Promotes Pancreatic Cancer Invasion , 2006, Annals of surgery.

[17]  C. Cooke,et al.  Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma , 2006, Oncogene.

[18]  L. Ellis,et al.  Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer , 2006, Clinical Cancer Research.

[19]  J. McCubrey,et al.  Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. , 2005, Cancer research.

[20]  M. Raffeld,et al.  Increased Expression of Insulin-Like Growth Factor I and/or Its Receptor in Gastrinomas Is Associated with Low Curability, Increased Growth, and Development of Metastases , 2005, Clinical Cancer Research.

[21]  M. Kaneki,et al.  Inducible Nitric-oxide Synthase and NO Donor Induce Insulin Receptor Substrate-1 Degradation in Skeletal Muscle Cells* , 2005, Journal of Biological Chemistry.

[22]  Eriko Tokunaga,et al.  S-Nitrosylation-dependent Inactivation of Akt/Protein Kinase B in Insulin Resistance* , 2005, Journal of Biological Chemistry.

[23]  Anne Jarry,et al.  Position in Cell Cycle Controls the Sensitivity of Colon Cancer Cells to Nitric Oxide-Dependent Programmed Cell Death , 2004, Cancer Research.

[24]  E. Wouters,et al.  Nitric oxide represses inhibitory κB kinase through S-nitrosylation , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Y. Vodovotz,et al.  Adenoviral Gene Transfer of the Human Inducible Nitric Oxide Synthase Gene Enhances the Radiation Response of Human Colorectal Cancer Associated with Alterations in Tumor Vascularity , 2004, Cancer Research.

[26]  I. Fidler,et al.  Therapy of cancer metastasis by activation of the inducible nitric oxide synthase , 1998, Cancer and Metastasis Reviews.

[27]  C. Mancuso,et al.  Bilirubin and S-nitrosothiols interaction: evidence for a possible role of bilirubin as a scavenger of nitric oxide. , 2003, Biochemical pharmacology.

[28]  E. Borden,et al.  Suppression of NF-κB Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL* , 2003, Journal of Biological Chemistry.

[29]  J. Abbruzzese,et al.  A novel model system for studying the double-edged roles of nitric oxide production in pancreatic cancer growth and metastasis , 2003, Oncogene.

[30]  Varda Rotter,et al.  Nitric oxide-induced cellular stress and p53 activation in chronic inflammation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Y. Li,et al.  Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: therapeutic implications. , 2002, Cancer research.

[32]  J. Joseph,et al.  Doxorubicin-induced Apoptosis Is Associated with Increased Transcription of Endothelial Nitric-oxide Synthase , 2001, The Journal of Biological Chemistry.

[33]  A. Marette,et al.  Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resistance in muscle , 2001, Nature Medicine.

[34]  E. Choi,et al.  Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Wink,et al.  Effects of oxidative and nitrosative stress in cytotoxicity. , 2000, Seminars in perinatology.

[36]  R. Heller,et al.  Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. , 1999, Atherosclerosis.

[37]  M. Zeng,et al.  Fas-induced caspase denitrosylation. , 1999, Science.

[38]  G. Storme,et al.  Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation , 1999, British Journal of Cancer.

[39]  C. Harris,et al.  p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells , 1998, Nature Medicine.

[40]  B. Chait,et al.  A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction. , 1997, The Journal of biological chemistry.

[41]  J. Wands,et al.  A carboxy-terminal truncated insulin receptor substrate-1 dominant negative protein reverses the human hepatocellular carcinoma malignant phenotype. , 1996, The Journal of clinical investigation.

[42]  J. Wands,et al.  Overexpression of human insulin receptor substrate 1 induces cellular transformation with activation of mitogen-activated protein kinases , 1996, Molecular and cellular biology.

[43]  M. Korc,et al.  Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. , 1995, Cancer research.

[44]  P. Kuo,et al.  The Emerging Multifaceted Roles of Nitric Oxide , 1995, Annals of surgery.

[45]  M. Currie,et al.  A fluorometric assay for the measurement of nitrite in biological samples. , 1993, Analytical biochemistry.

[46]  L. Ignarro,et al.  Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Moncada,et al.  Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor , 1987, Nature.